Across TCGA pan-cancer cohorts, RN7SL162P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RN7SL162P’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where RN7SL162P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL162P is over-expressed in tumor.
LUSC are the cancer types where RN7SL162P tumor–normal differential expression is most reproducible.